Pain management in children with sickle cell disease

Pediatric Drugs

Volumn 5, Issue 4, 2003, Pages 229-241

  Stinson, Jennifer ^a   Naser, Basem ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIPRURITIC AGENT; COCODAMOL; CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPHENHYDRAMINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; KETOROLAC; LAXATIVE; METHADONE; MORPHINE; NALBUPHINE; NALOXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; PARACETAMOL; PETHIDINE; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNINDEXED DRUG;

ADDICTION; ANALGESIA; ARTERY OCCLUSION; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CONSTIPATION; DISEASE COURSE; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; HEMOLYTIC ANEMIA; HOSPITAL ADMISSION; HUMAN; ISCHEMIA; MORBIDITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REHYDRATION; RESPIRATION DEPRESSION; REST; REVIEW; REYE SYNDROME; SEIZURE, EPILEPSY AND CONVULSION; SICKLE CELL ANEMIA; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VOMITING; WITHDRAWAL SYNDROME;

EID: 0037269859     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305040-00003     Document Type: Review

References (70)

1. Wang WC, Lukens JN. Sickle cell anemia and other sickling syndromes. In: Lee GR, Forester J, Lukens J, et al., editors. Wintrobe's clinical hematology. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999: 1346-82
2. Friedman J, Jarvis A, Kirby MA, et al. Guidelines for inpatient management of children with sickle cell disease. Toronto (ON): The Hospital for Sick Children, 2000
3. Kaul DK, Fabry ME, Nagel RL. The pathophysiology of vascular obstruction in the sickle syndromes. Blood Rev 1996; 10: 29-44
4. Shapiro BS. Management of painful episodes in sickle cell disease. In: Schechter NL, Berde CB, Yaster M, editors. Pain in infants, children, and adolescents. Baltimore (MD): Williams & Wilkins, 1993: 385-409
5. Franck LS, Treadwell M, Jacob E, et al. Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. J Pain Symptom Manage 2002; 23: 114-20
6. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84: 643-9
7. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. The Cooperative Study of Sickle Cell Disease. Blood 1997; 89: 1787-92
8. Yaster M, Kost-Byerly S, Maxwell LG. The management of pain in sickle cell disease. Pediatr Clin North Am 2000; 47: 699-710
9. Ballas SK. Sickle cell pain: progress in pain research and management. Vol 11. Seattle (WA): IASP Press, 1998
10. Shapiro BS, Dinges DF, Orne ED, et al. Home management of sickle-cell-related pain in children and adolescents: Natural history and impact on school attendance. Pain 1995; 61: 139-44
11. Beyer JE, Simmons LE, Woods GM, et al. A chronology of pain and comfort in children with sickle cell disease. Arch Pediatr Adolesc Med 1999; 153 (9): 913-20
12. Conner-Warren RL. Pain intensity and home pain management of children with sickle cell disease. Iss Compr Pediatr Nurs 1996, 195
13. Barbarin OA, Whitten CF, Bonds SM. Estimating rates of psychosocial problems in urban and poor children with sickle cell anemia. Health Soc Work 1994; 19: 112-9
14. Eaton ML, Haye JS, Armstrong FD, et al. Hospitalizations for painful episodes: association with school absenteeism and academic performance in children and adolescents with sickle cell anemia. Issues Compr Pediatr Nurs 1995; 18 (1): 1-9
15. Fuggle P, Shand PAX, Gill LJ, et al. Pain, quality of life, and coping in sickle cell disease. Arch Dis Child 1996; 75: 199-203
16. Graumlich SE, Powers SW, Byars KC, et al. Multidimensional assessment of pain in pediatric sickle cell disease. J Pediatr Psychol 2001; 26: 203-14
17. Gil KM, Anthony KK, Carson JW, et al. Daily coping practice predicts treatment effects in children with sickle cell disease. J Pediatr Psychol 2001; 26: 163-73
18. Burlew K, Telfair J, Colangelo L, et al. Factors that influence adolescent adaptation to sickle cell disease. J Pediatr Psychol 2000; 25: 287-99
19. Benjamin LJ, Dampier CD, Jacox AK, et al. Guidelines for the management of acute and chronic pain in sickle cell disease. APS clinical practice guidelines. No. 1. Glenview (IL): American Pain Society, 1999: 12-3
20. Beyer JE. Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell Disease. J Pain Symptom Manage 2000; 19: 63-72
21. Schechter NL. The management of pain in sickle cell disease. In: McGrath PJ, Finley GA, editors. Chronic and recurrent pain in childhood: progress in pain research. Vol. 13. Seattle (WA): IASP Press, 1999: 99-114
22. Elander J, Midence K. A review of evidence about factors affecting quality of pain management in sickle cell disease. Clin J Pain 1996; 12: 180-93
23. Fertleman CR, Gallagher A, Rossiter MA. Evaluation of a fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences. BMJ 1997; 315: 650
24. Sutton M, Atweh GF, Cashman TD, et al. Resolving conflicts: misconceptions and myths in the care of the patient with sickle cell disease. Mt Sinai J Med 1999; 66: 282-5
25. Shapiro BS, Benjamin LJ, Payne R, et al. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage 1997; 14: 168-74
26. Weissman DE, Haddox JD. Opioid pseudoaddiction: an iatrogenic syndrome. Pain 1989; 36: 363-6
27. Ballas SK. Sickle cell disease: current clinical management. Semin Hematol 2001; 38: 307-14
28. Franck LS, Greenberg CS, Stevens B. Pain assessment in infants and children. Pediatr Clin North Am 2000; 47: 487-512
29. Beyer JE, Platt AF, Kinney TR, et al. Practical guidelines for the assessment of children with sickle cell disease. J Soc Pediatr Nurs 1999; 4: 61-73
30. Merkel S, Voepel-Lewis T, Shayevitz J, et al. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs 1997; 23: 293-7
31. McGrath PJ, Johnson G, Goodman JT, et al. The CHEOPS: a behavioral scale to measure postoperative pain in children. In: Fields HL, Dubner R, Cervero F, editors. Advances in pain research and therapy. Vol. 9. New York: Raven Press, 1985: 395-402
32. Gil KM, Phillips G, Edens J, et al. Observation of pain behaviors during episodes of sickle cell disease pain. Clin J Pain 1994; 10: 128-32
33. Beyer JE, Knott C. Construct validity estimation for the African-American and Hispanic Oucher scale. J Pediatr Nuts 1998; 13: 20-31
34. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs 1988; 14: 9-17
35. Savedra MC, Tesler MD, Holzemer WL, et al. Testing a tool to assess post-operative pediatric and adolescent pain. In: Tyler DC, Krane RJ, editors. Advances in pain research and therapy. Vol. 15. New York: Raven Press, 1990: 85-94
36. Varni JW, Thompson KL, Janson V. The Varni/Thompson pediatric pain questionnaire (I): chronic musculoskeletal pain in juvenile rheumatoid arthritis. Pain 1987; 28: 27-38
37. World Health Organization. Cancer relief 1986. Geneva: Office of Publications, World Health Organization, 1986
38. Tobias J. Weak analgesics and nonsteroidal antiinflammatory agents in the management of children with acute pain. Pediatr Clin North Am 2000; 47 (3): 527-43
39. Hardwick WE, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care 1999; 15: 179-82
40. Houck CS, Wilder RT, McDermott JS, et al. Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system. J Pediatr 1996; 129: 292-6
41. Grisham JE, Vichinshy EP. Ketorolac versus meperidine in vaso-occlusive crisis: a study of safety and efficacy. Int J Pediatr Hematol Oncol 1996; 3: 239-47
42. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330: 733-7
43. Woods GM, Parson PM. Strickland DK. Efficacy of nalbuphine as a parenteral anaglesic for the treatment of painful episodes in children with sickle cell disease. J Assoc Acad Minor Phys 1992; 3: 90-2
44. Nadvi SZ, Sarnaik S, Ravindranath Y. Low frequency of meperidine-associated seizures in sickle cell disease. Clin Pediatr 1999, 462
45. Jacobson S, Kopecky EA, Joshi P, et al. Randomized trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet 1997; 350 (9088): 1358-61
46. Pegelow CH. Survey of pain management therapy provided for children with sickle-cell disease. Clin Pediatr 1992; 31: 211-4
47. Turner E, Shapiro B. Pharmacological management of pain. In: Shapiro B, Schechter N, Ohene-Frempong K, editors. The genetic resource, sickle cell disease-related pain: assessment and management. Mt Desert (ME): New England Regional Genetics Group, 1994: 27-38
48. Holbrook CT. Patient-controlled analgesia pain management for children with sickle cell disease. J Assoc Acad Minor Phys 1990; 1: 93-6
49. Shapiro BS, Cohen DE, Howe CJ. Patient-controlled analgesia for sickle cell-related pain. J Pain Symptom Manage 1993; 8: 22-8
50. Schechter NL, Berrien FB, Katz SM. The use of patient-controlled analgesia in adolescents with sickle-cell pain crisis: a preliminary report. J Pain Symptom Manage 1988; 3: 109-13
51. Stinson J, Naser B. Analgesie autocontrolee chez les enfants atteints d'anemie falciforme: L'experience d'un centre canadien. Doul et Analg 2000; 1: 21-6
52. Trentadue NO, Kachoyeanos MK, Lea G. A comparison of two regimens of patient-controlled analgesia for sickle cell disease. J Pediatr Nurs 1998; 13: 15-9
53. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. Pediatr Hematol Oncol 1992; 9: 317-26
54. Cole TB, Sprinkle RH, Smith SJ, et al. Intravenous narcotic therapy for children with severe sickle cell crisis. Am J Dis Child 1986; 140: 1255-9
55. Palozzi L, Stinson J. Patient controlled analgesia: nursing self-learning module. Toronto (ON): The Hospital for Sick Children. 2000
56. Monitto CL, Greenberg RS, Kost-Byerly S, et al. The safety and efficacy of parent-/nurse-controlled analgesia in patients less than six years of age. Anesth Analg 2000; 91: 573-9
57. Yaster M, Tobias JR, Billette C, et al. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis. Pediatrics 1994; 93: 310-5
58. Tobias JD. Indications and application of epidural anesthesia in a pediatric population outside the perioperative period. Clin Pediatr 1993; 32 (2): 81-5
59. Christensen ML, Wang WC, Harris S, et al. Transdermal fentanyl administration in children and adolescents with sickle cell disease. J Pediatr Hematol Oncol 1996; 18: 372-6
60. Dampier CD, Setty BN, Logan J, et al. Intravenous morphine pharmacokinetics in pediatric patients with sickle-cell disease. J Pediatr 1995; 126: 461-7
61. Koumoukelis H. Paediatric pain management dosing guidelines. Toronto (ON): Department of Anaesthesia, The Hospital for Sick Children, 2002
62. Walco GA, Erickson CJ, Eckman J. Non-pharmacologic management of pain. In: Shapiro BS, Schechter NL, Ohene-Frempong K. editors. The genetic resource, sickle cell disease-related pain: assessment and management. Mt Desert (ME): New England Regional Genetics Group, 1994: 39-42
63. Anie KA, Green J. Psychological therapies for sickle cell disease and pain (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Oxford Update Software. 2001
64. Dinges DF, Whitehouse WG, Orne EC, et al. Self-hypnosis training as an adjunctive treatment in the management of pain associated with sickle cell disease. Int J Clin Exp Hypn 1997; 45 (4): 417-32
65. Thomas VN, Wison-Barnett J, Goodhart F. The role of cognitive-behavioral therapy in the management of pain in patients with sickle cell disease. J Advan Nurs 1998; 27: 1002-9
66. Cozzi L, Tyron WW, Sedlacek K. The effectiveness of biofeedback-assisted relaxation in modifying sickle cell crisis. Biofeedback Self Regul 1987; 12: 51-61
67. National Institutes of Health. Acupuncture: NIH consensus statement 1998. Bethesda (MD): National Institutes of Health, 1998
68. National Institutes of Health Technology Assessment Panel. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. JAMA 1996; 276: 313-8
69. Wang WC, George SL, Willimas JA. Transcutaneous electrical nerve stimulation treatment of sickle-cell pain crisis. Acta Haematol 1988; 80: 99-102
70. Zeltzer L, Dash J, Holland JP. Hypnotically induced pain control in sickle cell anemia. Pediatrics 1979; 64: 533-6